148 results about "Protective antibody" patented technology

An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols.

The invention discloses a pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen and application thereof and belongs to the field of biological vaccines. The pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen adopts a strategy of an antigenized antibody, after main antigen epitopes of a plurality of strains of pig foot-and-mouth disease virus O-type are connected in series reasonably, the plurality of strains of pig foot-and-mouth disease virus O-type are coupled with a pig intravenous gamma globulin (IgG) heavy chain constant region to construct the pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen, and after ration through a Bio-Rad protein ration kit, the pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen and recombination foot-and-mouth disease virus 3D protein are matched to prepare the vaccines. Animal immunity testing results show that the vaccines can stimulate an organism to generate high-titer protective antibodies when the vaccines are used independently or matched with the recombination foot-and-mouth disease virus 3D protein to be used, an antibody level is higher than a national standard, and good application prospects are achieved.

The invention discloses a water-in-oil-in-water adjuvant vaccine and a preparation method thereof. The adjuvant vaccine is composed of an internal water phase, a middle oil phase used for cladding the internal water phase, and an external water phase for cladding the middle oil phase. The external water phase comprises: a composite surfactant, a hydrophilic surfactant and mormal saline. The middle oil phase consists of: a lipophilic surfactant, a stabilizer and mineral oil. The internal water phase comprises: an immunopotentiator solution, the hydrophilic surfactant, and an inactivated antigen solution. The W/O/W (water-in-oil-in-water) type adjuvant vaccine provided in the invention can induce an immunoreaction earlier than traditional W/O (water-in-oil) type adjuvant vaccines, and can make experimental animals obtain earlier protective antibodies. The vaccine has good absorption, and causes a small inflammatory response at an inoculation site. The adjuvant vaccine disclosed in the invention has better stability than existing W/O/W type vaccines, and the antibody generation speed is fast.

The invention discloses a genotype VII Newcastle disease virus marker vaccine strain and an application thereof, and belongs to the field of genotype VII Newcastle disease virus marker vaccine strain rescue and application. A built Newcastle disease virus reverse genetic operating platform is utilized for enabling NP protein of a G7 strain to miss 18 amino acids and conducting mutation on F-protein cleavage loci, and the highly-weak virulence and high-virus titer genotype VII Newcastle disease virus marker vaccine strain MG7-NPdelta18+Fmut is rescued through screening. The microbial preservation serial number is CCTCC NO: V201505. The marker vaccine strain has the biological characteristics of high growth titer and low virulence in chick embryos and is genetically stable. The immune protection test result shows that the marker vaccine strain is good in immunogenicity, capable of inducing high-level protective antibodies, and capable of completely protecting immunized chicken, can be used for preventing and controlling a currently-popular genotype VII Newcastle disease virus and lays the foundation of identifying vaccine immunity and wild virus infection.

The present disclosure provides a method of inducing a cross-protective immune response in a subject against a pathogen, such as influenza, comprising administering a first unique pathogen antigen to the subject; and administering a second unique pathogen antigen 3-52 weeks after a); wherein the second unique pathogen antigen and the first unique pathogen antigen are immunologically distinct but share conserved sites that are not normally immunogenic for antibodies. Also disclosed herein are assays for detecting cross-protective antibodies, methods of generating novel cross-protective antibodies. Further provided are novel antibodies against influenza.

Disclosed herein are antigens that stimulate protective antibodies against enterotoxigenic Escherichia coli. Also disclosed herein are proteins encoded by cssA and cssB genes as well as constructs containing the genes and methods of using thereof.

The invention is directed to the use of (i) a first antigen corresponding to a target antigen of interest, together with (ii) a second antigen, corresponding to a modified form of the target antigen, whose rate of intracellular proteolytic degradation is increased, enhanced or otherwise elevated relative to the first antigen, in compositions and methods for inducing both humoral and cellular immunity in an individual. The ability to provide compositions, which are capable of inducing both host-protective antibody and cell-mediated immune responses, facilitates the generation of immunogenic compositions capable of combating, inter alia, conditions that have long latency periods and, therefore, benefit from the dual approach of prophylaxis and therapy in one delivery.

The present invention relates to the identification of a subunit vaccine to prevent or treat infection of Epstein Barr Virus. In particular, EBNA-1 was identified as a vaccine antigen. In a specific embodiment, a purified protein corresponding to EBNA-1 elicited a strong CD4⁺ T cell response. The responsive CD4⁺ T cell are primarily T_H1 in function. EBNA-1 is an attractive candidate for a protective vaccine against EBV, and for immunotherapy of EBV infection and neoplasms, particularly with dendritic cells charged with EBNA-1.

The invention relates to a method for a tetanus toxin receptor binding domain Hc to be subjected to high-level soluble expression in Escherichia coli through nucleotide sequence optimization. According to the sequencing result of a domestic C.Tetani virulent strain CMCC64008, the tetanus toxin receptor binding domain Hc sequence is analyzed and optimized, the optimized sequence is SEQ ID No.1 and the coded protein sequence is SEQ ID No.2. The synthesized Hc gene is linked into an expression vector pET32a(+) after undergoing double enzyme digestion, the recombinant Hc is subjected to high soluble expression in Escherichia coli and the target protein accounts for about 46% of the total protein in the supernatant undergoing bacteriociasis. After QFF column purification, phenyl hydrophobic column purification and SP column purification, the purity of the target protein can be more than 95% and the yield thereof is more than 300mg/L. The recombinant protein prepared by the method of the invention has good immunogenicity, can induce the mice to produce high-titre protective antibodies and can resist attack of high-dose lethal toxins. The method has extensive application prospect in large-scale high-level preparation of the tetanus toxin recombinant subunit vaccine Hc.

The invention relates to a preparation method of a high-density fermented and freeze-dried active microbial agent of a forage anti-diarrhea yeast, and belongs to the field of an agriculture biotechnology. The method comprises the following steps: inoculating an original starting strain (Saccharomyces boulardii, ATCC MYA-796) into yeast leaching peptone powder glucose liquid culture medium after activating; cultivating at 30 DEG C for 12-16 hours at 200-250rpm as a seed solution; inoculating the seed solution by 10% of inoculation amount, cultivating at 30 DEG C for 12 hours at 800rpm in liquid-expanded yeast leaching peptone powder glucose liquid culture medium, and then feeding 25% glucose for 6 hours, wherein the feeding amount is 20ml/h/L of fermentation liquor; centrifugally collecting thalli and adding protective agents (8% of glycerinum, 7.5% of skim milk powder, 7.5% of mycose and 0.9% of sodium chloride), wherein the mixing ratio of the protective agents to the thalli is 2:1; stewing and balancing for an hour after evenly mixing; pre-cooling at -80 DEG C for 12 hours, and then freeze-drying the thalli in a vacuum freezer dryer; weighing freeze-dried powder to count viable bacteria, wherein the viable bacteria count achieves 1.4*10<10> CFU/g.

The invention relates to a stable lyophilized preparation of a recombinant human anti-CD20 monoclonal antibody. The lyophilized preparation is composed of the recombinant human anti-CD20 monoclonal antibody, a buffer system, a protective agent, an excipient and the like. The lyophilized preparation provided by the invention has a loose, full and complete appearance, has stability significantly superior to that of liquid preparations, and is suitable for long-term storage.

The invention belongs to the technical field of biological medicine, and concretely relates to a swine fever virus subunit vaccine and a preparation method and a purpose thereof. The invention provides a kluyveromyces marxianus yeast recombination strain used for preparing the swine fever virus subunit vaccine. The recombination strain is constructed by the following steps: swine fever virus envelope protein E2 is intercepted, through codon optimization, a coding sequence of the swine fever virus mE2 protein is obtained, and then is cloned to a kluyveromyces marxianus yeast expression vector,and the kluyveromyces marxianus yeast host strain is transformed. The invention also provides the method for preparing the swine fever virus subunit vaccine, which comprises the following steps: the kluyveromyces marxianus yeast host strain is subjected to recombination expression by using mE2, steps of culture, centrifugation, cell disruption, and separating purifying are carried out to obtain the swine fever virus mE2 protein antigen, and the purified antigen and an adjuvant are subjected to complex formulation to prepare the swine fever virus subunit vaccine. The injection immunotherapy ofswine fever virus mE2 protein recombination subunit vaccine can obtain a protective IgG antibody, and the subunit vaccine can reduce and prevent the swine fever virus infection-related disease.

Recombinant hybrid streptococcal M protein antigens are provided which elicit protective antibodies against Group A streptococci and prevent rheumatic fever. Recombinant hybrid genes which encode the antigen are provided. Vaccine compositions and methods of administering the compositions are provided to elicit immunity against Group A streptococci.

The invention relates to a special rhodococcus ruber (CGMCC NO. 17012) fermentation method, a preparation process of adjuvants with different dosage forms and an application as an adjuvant in animalvaccines. Rhodococcus ruber strains are separated from a farm and obtained through single colony cloning purification and identification, the invention provides a special fermentation process where the strain inactivation product is used as an animal vaccine adjuvant, and provides a preparation process of different dosage forms of adjuvants containing the strain and the product. Animal experimentsprove that when the adjuvant product is used for univalent or multivalent animal vaccines, particularly Newcastle disease inactivated vaccine, avian influenza inactivated vaccine and swine fever livevaccine, definite non-specific immune enhancement effect can be provided, specifically, the antibody peak value level induced by the animal vaccine is obviously improved, the time for producing the protective antibody level is advanced, the antibody maintenance period is prolonged, and the immune effect of the animal vaccines is enhanced.

The invention discloses a bovine A-type foot-and-mouth disease multi-epitope recombinant vaccine, and a preparation method and an application thereof, and belongs to the field of veterinary vaccine research. The preparation method comprises the following steps: carrying out reasonable serial connection on the dominant antigen epitopes of bovine A-type foot-and-mouth disease virus representative strains once pandemic in China by adopting an antigenized antibody strategy and a brand new reverse vaccinology technology and strategy, coupling with a bovine IgG immunostimulatory fragment (IgG heavy chain constant region), cloning into a prokaryotic expression vector to construct a recombinant expression vector, transforming Escherichia coli cells to express a recombinant antigen, purifying by adopting Ni-NAT column chromatography, quantifying by a Bio-Rad protein quantification kit, and preparing the vaccine individually or combining with a recombinant foot-and-mouth disease virus 3D protein. A result of animal immune experiments shows that the recombinant protein or combined vaccine can stimulate the body to produce a protective antibody with high titer and also can protect immune animals against a virus attack, so the bovine A-type foot-and-mouth disease multi-epitope recombinant vaccine has a good application prospect.

The invention discloses an EV71 subunit vaccine of a mixed adjuvant and a preparation method thereof. According to the vaccine, C4 sub-type EV71 virus VP1 protein is used as an antigen, and aluminum hydroxide and monophosphoryl lipid A are used as a mixed adjuvant. VP1 protein which is expressed and purified by escherichia coli and does not have any label is used as an antigen; the prepared protein is combined with an aluminum adjuvant under a denaturing condition, is subjected to detergence determination, and is mixed with an MPLA adjuvant to immune mice; and the prepared polyvalent antibody can be used for specifically neutralizing the EV71 virus to generate a neutral protective antibody having a titer nearly 1:128. Compared with an EV71 inactivated vaccine in current clinical tests, the human enterovirus 71 type subunit vaccine has the characteristics of low cost, simple operation, high safety, easy large-scale production and the like in the production process. The vaccine can generate relatively good immunogenicity in a human body, has a relatively high titer of the neutralizing antibody, and is an alternative vaccine with potential clinical application value.

The invention discloses a bovine A-type foot-and-mouth disease broad-spectrum multi-epitope recombinant vaccine, and a preparation method and an application thereof, and belongs to the field of veterinary vaccine research. The preparation method comprises the following steps: carrying out reasonable serial connection on the major antigen epitopes of pandemic in China and bovine A-type foot-and-mouth disease virus representative strains recently pandemic in countries bordering China by adopting a brand new reverse vaccinology idea and strategy, coupling with a bovine IgG heavy chain constant region, cloning into a prokaryotic expression vector to construct a recombinant expression vector, transforming Escherichia coli cells to express a recombinant antigen, purifying by adopting Ni-NAT column chromatography, quantifying by a Bio-Rad protein quantification kit, and preparing the vaccine individually or combining with a recombinant foot-and-mouth disease virus 3D protein. A result of animal immune experiments shows that the multi-epitope antigen or 3D protein combined vaccine can stimulate the body to produce a protective antibody with high titer and also can protect immune animals against a virus attack, so the bovine A-type foot-and-mouth disease broad-spectrum multi-epitope recombinant vaccine has a good application prospect.

Production of various Aeromonas hydrophila protective antigen monovalent and multivalent vitelline antibody and its usage in prevention of aquatic animal diseases are disclosed. It utilizes minor-protective antibody to make immune irritant composite egged hen and produce vitelline antibody product. It's safe, efficient, fast, has no harm and residue. It has more output, better immune-system development and functions of nutrients-added, disease-prevention and health-care.

The invention relates to a preparation and application of a vaccine immunity effect evaluation protein chip. By using the invention, whether corresponding protective antibodies are contained in bodies of vaccinated people or animals or not or whether the vaccines have protective effects after the people or animals are vaccinated for a period of time or not can be detected. In the invention, the protein chip is prepared on a modified substrate by using protective antigens of multiple disease pathogens or antigen material points of corresponding vaccines after being treated by different methods, protective antibodies of the multiple vaccines can be simultaneously detected through an experiment, and multiple specimens can be simultaneously analyzed; and multiple different signal detecting methods are obtained; the vaccine immunity effect evaluation protein chip provided by the invention has the advantages of speediness, accuracy, high throughput, high sensitivity and high specificity; and a new technology and a new product can be provided for the immunity effect evaluation of the vaccine.

The invention belongs to the technical fields of veterinary microbiology and zoonotic diseases, and in particular relates to application of immunogenic protein genes of streptococcus suis type-2 for separating, cloning and expressing exocellular peptides and recombinant proteins of the encoded proteins in vaccine and diagnosis. In the invention, a new immunogenic protein gene hp0245 is separated from SC-19 bacterial strains of streptococcus suis type-2 virulent strains, wherein DNA (hp0245EC) for encoding the exocellular peptides has nucleotide sequences represented in the sequence table SEQ ID No:1 and is encoded with 261 amino acids. The recombinant protein HP0245EC remains the immunogenic feature of the primitive protein, can provide effective immunological protection to the SC-19 bacterial strain of the streptococcus suis type-2 infected in mice and has potential application value of vaccine. The invention further comprises a composition and preparation method for a streptococcus suis type-2 HP0245-ELISA diagnostic reagent kit, and a preparation of hp0245EC for cloning hp0245EC escherichia coli; the recombinant escherichia coli has been preserved in the China Center for Type Culture Collection (CCTCC) and the preservation number is CCTCC No: M2010258.